An interventional study of Low molecular weight heparin and non anticoagulant therapy group in Thrombosis, sponsored by First Affiliated Hospital of Chongqing Medical University. Completed at 1 site in China. Open to participants aged 20 Years to 85 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-06-24.
Sponsored by First Affiliated Hospital of Chongqing Medical University · Not applicable, Interventional, and Prevention
Many guidelines at home and abroad advocate that arteriovenous fistula should be the first choice of permanent vascular access, but it is easy to form thrombus in a short time after arteriovenous fistula molding, resulting in internal fistula stenosis or occlusion. In this study, the investigators plan to screen the patients with arteriovenous fistula in the blood purification center of our hospital. Through the study design of random grouping and open label, the investigators will discuss the use of low molecular weight heparin or warfarin to prevent thrombosis in a short period of time after arteriovenous fistula operation. According to the research results, the investigators will understand efficacy and safety of short-term postoperative anticoagulant therapy to prevente thrombosis in arterovenous fistula.
1,506 studies on the registry are indexed under Thrombosis; 238 are open to participants now.
This study's enrollment of 287 is above the median of 106 across 849 interventional studies indexed under Thrombosis.
Browse Thrombosis studies →First Affiliated Hospital of Chongqing Medical University is the lead sponsor of 95 studies on the registry; 42 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria.
Patients in the anticoagulant group received low-dose subcutaneous injection of low molecular weight heparin for prevention of AVF thrombosis, starting 12-24 hours after surgery. For patients weighing less than 80kg, enoxaparin sodium 4000IU was administered once daily, while for those weighing over 80kg, enoxaparin sodium 4000IU was administered every 12 hours. After discharge, these patients were switched to oral low-dose warfarin for anticoagulation, with a daily dose of 1.25mg (half tablet) on dialysis days, and 2.5mg/day on non-dialysis days. Patients with significantly excessive body weight may be considered for a daily dose of 2.5mg, with a total treatment duration of 4 weeks.
Drug: Low molecular weight heparin
Patients in the control group did not receive anticoagulants postoperatively, but both groups routinely received antiplatelet therapy.
Other: non anticoagulant therapy group
patients began to use low molecular weight heparin or warfarin sodium tablets.
Also known as: warfarin sodium tablets
no anticoagulant was used after operation.
Blood flow of arteriovenous fistula
Blood flow of arteriovenous fistula during hemodialysis from 6 months after operation
Time frame: up to 12 months
arteriovenous fistula dysfunction or occlusion
The proportion of arteriovenous fistula dysfunction or occlusion
Time frame: up to 12 months
Active bleeding events
such as,bleeding of surgical wound, intracranial, digestive tract and urinary tract, ecchymosis and ecchymosis of skin.
Time frame: up to 12 months
arteriovenous fistula dysfunction or occlusion
The time of arteriovenous fistula dysfunction or occlusion
Time frame: up to 12 months
AVF Maturation Failure AVF Maturation Failure AVF Maturation Failure AVF Maturation Failure AVF maturation failure
AVF maturation failure two months postoperatively
Time frame: up to 2 months
coagulation index
Change of coagulation index
Time frame: up to 12 months
Platelet
Changes of platelet indexes
Time frame: up to 12 months
Number of hospitalization
Number of hospitalization due to arteriovenous fistula thrombosis.
Time frame: up to 12 months
Death
Death from any cause
Time frame: up to 12 months
Plan to share: No
No publications or documents are linked to this record.
This study is completed, as verified in Jun 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
First Affiliated Hospital of Chongqing Medical University